tbuckley/cabot-search huggingface dataset:
AB0698 Clinimetric Properties of The Asas Health Index in Patients with Axial Spondyloarthritis: Validation in An Italian Cohort
Authors: M. Di Carlo, V. Lato, M. Carotti, F. Salaffi
Journal: Annals of the Rheumatic Diseases (2016)

Background  Over the last decades, many efforts have been conducted to develop useful tool for the evaluation of disease activity. However, since the development of Assessment of SpondyloArthritis international Society Health Index (ASAS HI), no specific freely available questionnaires to describe the overall picture of impairments, limitations and restrictions in activities or social partecipation.  Objectives  The aims of this study were to test the feasibility, reliability, and construct validity of the ASAS HI, in order to compare its clinimetric properties with the current available measures of disease activity, functional limitation and health status assessments in patients with axSpA.  Methods  A cohort of 140 consecutive axSpA has been the object of study. The feasibility has been determined by the percentage of patients who were able to complete the questionnaire by themselves and by the time employed to fill the ASAS HI. The reliability has been evaluated performing a test-rerest of the questionnaire within a week. The construct validity was examined in three ways. First, we examined construct convergent validity by correlating the scores of the ASAS HI with ASDAS-CRP/ESR, SASDAS, BASDAI, BASMI, BASFI, the ASQoL and EQ-5D. Secondly, we have created patient groups based on the patients9 activity ranks (ASDAS-CRP and SASDAS categorisation) within the cohort to assess discriminative accuracy. Additionally, to distinguish patients with active and non-active disease and to assess their respective cut-off points values, the receiver operating characteristic (ROC) curve analysis was used. Thirdly, we analyzed the contribution of demographic (age, sex, and disease duration) and clinical variables (number of comorbidity and disease activity by ASAS-CRP) to the attainment of an ASAS HI condition by stepwise logistic regression.  Results  The mean time to complete the ASAS HI was 114.9± 45.2 seconds (range 48 – 210 seconds). Coefficients of agreement between ASAS HI scores on first and second administrations were excellent and all items showed very good agreement (ICC =0.976; range 0.966 to 0.982). The ASAS HI was correlated significantly with all other comparator scores (p  Conclusions  The results reported in this study confirm the feasibility, reliability and validity of the ASAS HI in Italian patients with axSpA. Of particular interest appears the cut-off value of 4.0, under which could be identified the inactive disease. This value could represent an easily applicable starting point in daily clinical practice.  Disclosure of Interest  None declared
Tolerated, Low-Dose Deferasirox: Successful Three Cases of Aplastic Anemia and 34 Cases of MDS
Authors: Manabu Hirai, Ryousuke Yamamura, Hirohisa Nakamae, Yoshiki Terada, Atsushi Inoue, Mitsuharu Hashimura, Hiroyoshi Ichihara, Erina Sakamoto, Masayuki Hino
Journal: Blood (2012)
Glutathionylation of NF-Kb and Procaspase-3 Regulates Inducible Nitric Oxide Synthase Expression and Apoptosis of Chronic Myeloid Leukemia Cells
Authors: Abhishek Singh, Megha Dubey, Deepika Awasthi, Sheela Nagaroti, Manoj Barthwal, Rabindra Jena, Anil K Tripathi, Madhu Dikshit
Journal: Blood (2014)
STAT3: A Direct HMGA1 Gene Target Important in Lymphoid Malignancy.
Authors: Linda Resar, Surajit Dhara, Takita Felder Sumter, Mita Mukherjee, James Turkson, Rich Jove, Ossama Elbahloul, Peter Aplan, Ying-Wei Lin, Raka Bhattacharya
Journal: Blood (2006)
Donor T Cells Lacking IFN-Gamma Receptor Expression Enhance Donor Myeloid Engraftment and Decrease Early Acute Graft-Versus-Host Disease Mortality Following Allogeneic Bone Marrow Transplantation
Authors: Kai Sun, Minghui Li, Mark A. Hubbard, Lisbeth A. Welniak, William J. Murphy
Journal: Blood (2008)
Spontaneous and Experimental Leukæmia in Animals
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TET2 mRNA Expression in Bone Marrow Mononuclear Cells of the Patients with Myelodysplastic Syndromes and it's Clinical Significances
Authors: Zonghong Shao, Wei Wang, Rong Fu, Jun Wang, Lijuan Li, Erbao Ruan, Wen Qu, Yong Liang, Guojin Wang, Xiaoming Wang, Hong Liu, Jia Song, Yuhong Wu, Limin Xing, Jing Guan, Huaquan Wang
Journal: Blood (2011)
A Two-Fold Rise of BCR-ABL Transcript Levels Advises BCR-ABL Mutation Analysis in Imatinib-Treated Chronic Myeloid Leukemia (CML) - an Analysis of the Randomized CML-Study IV
Authors: Benjamin Hanfstein, Niklas Westhoff, Rüdiger Hehlmann, Susanne Saussele, Michael Lauseker, Thomas Ernst, Philipp Erben, Christian Dietz, Alice Fabarius, Ulrike Proetel, Susanne Schnittger, Stefan W. Krause, Joerg Schubert, Hermann Einsele, Mathias Hänel, Jolanta Dengler, Christiane Falge, Lothar Kanz, Andreas Neubauer, Michael Kneba, Frank Stegelmann, Michael Pfreundschuh, Cornelius F. Waller, Karsten Spiekermann, Gabriela M. Baerlocher, Markus Pfirrmann, Joerg Hasford, Wolf-Karsten Hofmann, Andreas Hochhaus, Martin C. Müller
Journal: Blood (2014)
Evaluation of quantitative PCR for early diagnosis of Pseudomonas aeruginosa infection in cystic fibrosis: a prospective cohort study
Authors: G. Héry-Arnaud, E. Nowak, J. Caillon, V. David, A. Dirou, K. Revert, M.-R. Munck, I. Frachon, A. Haloun, D. Horeau-Langlard, J. Le Bihan, I. Danner-Boucher, S. Ramel, M.-P. Pelletier, S. Rosec, S. Gouriou, E. Poulhazan, C. Payan, C. Férec, G. Rault, G. Le Gal, R. Le Berre
Journal: Clinical Microbiology and Infection (2016)
T Cells Expressing Engager and Costimulatory Molecules for the Immunotherapy of CD19+ Malignancies
Authors: Mireya Paulina Velasquez, Kota Iwahori, David L Torres, Sunitha Kakarla, Caroline Arber, Tania Rodriguez-Cruz, Claudia Gerken, Xiao-Tong Song, Stephen Gottschalk
Journal: Blood (2014)
SAT0051 Transcription Factor SOX5 Promotes Rheumatoid Arthritis Synovial Fibroblast Migration and Invasion by Regulating MMP9 Expression via Downregulated MIR-15A/MIR-16
Authors: W. Tan, Y. Shi, X. Feng, F. Wang, W. Xuan, M. Zhang
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> SOX5 is known as a transcription factor which primarily involved in the regulation of embryonic development, cell fate, and chondrogenesis. To date, little is known the effect of SOX5 on rheumatoid arthritis (RA). We previously reported association between younger age at onset of rheumatoid arthritis (RA) and a RANKL promoter SNP that conferred an elevated promoter activity after stimulation via binding to a transcription factor SOX5 (Arthritis Rheum 2010; 62(10):2864–75.). Subsequently, we confirmed that SOX5 could up-regulate RANKL expression in RA synovial fibroblast (SF) and participate in the bone erosion of RA. <h3>Objectives</h3> Here, we examine the effect of SOX5 on the migration and invasive characteristics of RA synovial fibroblasts. <h3>Methods</h3> Rheumatoid synovial fibroblasts cell line MH7A were treated with SOX5 small interfering RNA (SOX5-siRNA) and recombinant Adenovirus SOX5 expression vectors (Ad-SOX5). Migration and invasion and of RASF was assessed by transwell matrigel™ invasion chambers and collagen gel assays. Modulation of MMP9 expression in RASF was analyzed by real-time PCR, western blot, luciferase assay and Chromatin immunoprecipitation (ChIP). Collagen-induced arthritis (CIA) DBA/1 mouse locally injected with lentivirus-shSOX5 was used to examine the effect of SOX5 on MMP9 expression in vivo. <h3>Results</h3> Overexpression of SOX5 significantly induced cell migration, invasion and MMP-9 expression in RASF. Migration and invasion of RASF could be markedly decreased by silencing SOX5 expression but could be reverted by added the recombinant MMP9 cytokine into RASF. Overexpression of SOX5 enhanced the promoter activity of MMP9 in Hela cell. Chromatin immunoprecipitation (ChIP) showed approximately 3-fold enrichment of MMP9-specific DNA in anti-SOX5 immunoprecipitate in IL-6 treated MH7A, as compared to untreated cells. Silencing SOX5 resulted in significantly increased miR-15a/miR-16 expression in MH7A. The enhanced MMP-9 expression induced by Ad-SOX5 transfection could be inhibited by miR-15a/miR-16 mimics. Local silencing SOX5 in CIA mice inhibited the synovitis and bone erosion in CIA mice and accompanied by the markedly reduced MMP9 expression in synovium. <h3>Conclusions</h3> These findings indicated transcription factor SOX5 plays an important role in regulating the migration and invasion and production in RA SF by modulation MMP9 expression via downregulated miR-15a/miR-16, suggesting SOX5 as a potential therapeutic target for the treatment of RA. <h3>Disclosure of Interest</h3> None declared
A simple, combined test can improve the diagnosis of autoimmune urticaria
Authors: K. Hajdu, B. Irinyi, E. Gyimesi, A. Kapitány, Zs. Dajnoki, Zs. Bata‐Csörgő, Á. Kinyó, F. Kiss, K. Gáspár, A. Szegedi
Journal: British Journal of Dermatology (2016)
Importance of Measuring Circulating ADAMTS13 Immune Complexes in Addition to Free Antibodies in Patients with Acquired TTP
Authors: Silvia Ferrari, Barbara Plaimauer, Bernadette Gruber, Kristina Palavra, Peter L Turecek, Hartmut J. Ehrlich, Hanspeter Rottensteiner, Friedrich Scheiflinger
Journal: Blood (2012)
Lymphoma Associated Chromosomal Abnormalities Can Be Easily Detected by FISH on Tissue Imprints. an Underused Diagnostic Alternative.
Authors: Ismael Buño, Paola Nava, Angela Alvarez-Doval, Ainhoa Simon, Gonzalez-Pardo Gema, Federico Alvarez-Rodriguez, Jose L. Diez-Martin, Javier Menarguez
Journal: Blood (2004)
FRI0320 Disease Severity in Patients with Discoid Lupus Erythematosus from A Real-World Setting
Authors: B. Hoskin, S. Lobosco, D. Bell, A. Kao, S. Hall, S.-Y. Chen
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Real-world data on the severity of discoid lupus erythematosus (DLE) are scarce, limiting our understanding of the clinical course of this chronic disease that disproportionately affects minorities. <h3>Objectives</h3> To assess the clinical burden and unmet need by disease severity in DLE patients. <h3>Methods</h3> Data were drawn from a 2013 multinational survey of clinical practice that included 101 dermatologists across the US and EU (France, Germany, Italy, Spain &amp; UK). Dermatologists completed the patient record (PRFs) for their next five consulting patients with cutaneous lupus erythematosus. The present analyses were a subset of patients with DLE, categorized by dermatologists into two groups based on their severity at the current visit: 1) mild, and 2) moderate/severe. The two groups were compared in bivariate analyses, using Mann-Whitney-U tests and Fisher9s exact tests. <h3>Results</h3> Final analyses included 315 DLE patients; 72% were female; mean age at diagnosis=39.7 years; mean disease duration=4.4 years. At diagnosis, 74% of DLE patients had moderate-to-severe DLE, and 10% had joints affected; at the current visit, the corresponding proportions were 27% and 11%. Among DLE patients currently presenting as moderate-to-severe, achieving remission was less common (14% vs. 60% among mild DLE patients; p≤0.0001). Patients moderate-to-severe during the present visit were more likely to be currently flaring (18% vs. 4%; p≤0.0001) or have flared in the last 12 months (37% vs. 16%; p=0.0001). Finally, dermatologist satisfaction with the level of control from treatment was also significantly lower amongst currently moderate/severe DLE patients (39% satisfied vs. 91% mild; p≤0.0001), with dermatologists reporting that better control can be achieved in over a quarter of moderate/severe DLE patients (27% vs. 3% mild; p≤0.0001). <h3>Conclusions</h3> Across regions and despite an average of 4 years since diagnosis, a sizeable proportion of DLE patients (nearly one-third) in clinical care were moderate-to-severe at their current visit, indicating persistence, relapse or worsening. Results suggest an unmet need for better disease control. This study contributes to the scant literature on DLE by informing our understanding of the disease in real-world settings of clinical care, and may help development of appropriate new interventions amongst those not currently controlled under standard therapies. <h3>Acknowledgement</h3> These analyses were supported by Biogen. <h3>Disclosure of Interest</h3> B. Hoskin Employee of: Adelphi Real World, S. Lobosco Employee of: Adelphi Real World, D. Bell Employee of: Adelphi Real World, A. Kao Employee of: Employee at Biogen at the time of the research, S. Hall Shareholder of: Biogen, Employee of: Biogen, S.-Y. Chen Shareholder of: Biogen, Employee of: Biogen
Serial Comprehensive Geriatric Evaluation in Elderly Head and Neck Cancer Patients Undergoing Radiotherapy
Authors: P.R. Debruyne, M. Lycke, T. Boterberg, H. Pottel, L. Goethals, N. van den Noortgate, F. Duprez, S. Rottey, K. Kargar-Samani, L. Pottel
Journal: Annals of Oncology (2012)
Reduced Intensity Conditioning Regimen of Autologous Hematopoietic Stem Cell Transplantation±Mitoxantrone Consolidation In Multiple Sclerosis
Authors: Andrei A Novik, Aleksey N Kuznetsov, Vladimir Y Melnichenko, Denis A Fedorenko, Andrei V Kartashov, Tatyana I Ionova, Kira A Kurbatova, Gary I Gorodokin
Journal: Blood (2010)
Surveillance Cultures In Pediatric Hematopoietic Stem Cell Transplantation: The Possibility Of Early Directed Antimicrobial Therapy For Bloodstream Infections With Throat Swabs
Authors: Hyery Kim, Ji Won Lee, Hyoung Jin Kang, Kyung Duk Park, Hee Young Shin, Hyo Seop Ahn
Journal: Blood (2013)
AB0577 Sleep Quality in Behcet's Disease Is Associated with Disease Activity, Depression, and Quality of Life in Korean Populations
Authors: S.-S. Kim, J. Lee, Y.S. Kim, H.-S. Kim, S.-J. Hong, H.-J. Jeong, C.-N. Son, J.-M. Kim, S.-H. Kim
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Behcet9s disease is a chronic, systemic vasculitis that can involve all sizes of blood vessels. Those complicated symptoms lead to the patient9s impairment of life quality as well as psychological problems. Sleep disturbance is one of the most particular concerns in patients with Behcet9s disease. It has been known that the disease activity of rheumatoid arthritis and ankylosing spondylosis is associated with the sleep quality. However, studies about the sleep quality of patients with Behcet9s disease in Korean population are limited. <h3>Objectives</h3> The purpose of this study was to find out the effects of sleep quality on Behcet9s disease in Korean population. We also investigated the relationship between depression, quality of life, other clinical findings of Behcet9s. <h3>Methods</h3> The study was performed by cross-sectional design in two tertiary hospitals. We met one hundred patients with Behcet9s disease, surveyed them face-to-face and conducted the chart review for more clinical informations. Sleep quality was assessed by the Korean version of Pittsburgh sleep quality index (PSQI). Disease activity of Behcet9s disease was evaluated by Behcet9s disease current activity form (BDCAF). Depression was assessed by the Korean version of Beck depression inventory second edition (BDI-2). Quality of life was assessed by the Korean version of the Leeds Behcet9s Disease Quality of Life Measure (BDQoL). <h3>Results</h3> Among 100 patients, median age was 51 [44.5–56.0] years, median disease duration was 77.5 [24.0–136.0] months and 31% were male. Those who met the diagnostic critera of fibromyalgia were 28 patients. The frequency of poor sleep quality (PSQI &gt;5) was 67%. Patients with poor sleep quality tend to have higher BDI2, BDCAF and pain VAS score (P&lt;0.001, P=0.028, and P=0.011). Female rate was significantly higher, and BDQoL was lower in poor sleeper group (P=0.004 and P&lt;0.001). Among 7 PSQI components, daytime dysfunction was higher in patients with high disease activity (P=0.03). Total PSQI score were strongly correlated with BDCAF score, BDI-2 score, BDQoL score, and pain VAS score (P=0.02, P&lt;0.001, P&lt;0.001, and P&lt;0.001, respectively). <h3>Conclusions</h3> The low quality of sleep is associated with disease activity, depression and quality of life in Korean patients with Behcet9s disease. We expect better disease control will improve the sleep quality. <h3>References</h3> Tascilar NF, Tekin NS, Ankarali H, Sezer T, Atik L, Emre U, Duysak S, Cinar F. J Sleep Res 2012;21:281–8. Melikoglu MA, Melikoglu M. Rheumatol Int 2010;30:941–6. <h3>Disclosure of Interest</h3> None declared
ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS AGED &gt; 70 Years.
Authors: Paola Finsinger, Massimo Breccia, Clara Minotti, Ida Carmosino, Laura Cannella, Paola Volpicelli, Federico Vozella, Caterina Stefanizzi, Giuseppina Loglisci, Giuseppe Cimino, Robin Foà, Roberto Latagliata
Journal: Blood (2009)
Long Term Follow-up of Recipients of Combined HLA-Matched Nonmyeloablative Bone Marrow and Kidney Transplantation for Multiple Myeloma with End-Stage Renal Disease.
Authors: Thomas R Spitzer, Megan Sykes, Nina Tolkoff Rubin, Tatsuo Kawai, Steven L McAfee, Bimalangshu Dey, Karen Ballen, Francis Delmonico, Susan Saidman, David H Sachs, Benedict Cosimi
Journal: Blood (2009)
SP0164 Problems in Conventional Therapy in Osteoarthritis: A Case Presentation
Authors: W.-Y. Kwok
Journal: Annals of the Rheumatic Diseases (2016)

In this case presentation a 57-year old male patient is illustrated, who suffers from non-inflammatory arthralgia due to osteoarthritis. He visits the outpatient clinic with the specific question for advice with respect to pain management, especially for his hand pain since he is a technician in a dental laboratory. However, non-steroidal anti-inflammatory drugs (NSAIDS) are contra-indicated by his ischemic cardiomyopathy, cerebral vascular accident, hypertension and ulcus duodeni in the past. <h3>Disclosure of Interest</h3> None declared
SAT0128 Secondary Sjögren's Syndrome in Rheumatoid Arthritis: Characteristics and Association with Joint Damage
Authors: O. Akkar, L. Ichchou
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid Arthritis (RA) is often associated with secondary Sjögren9s syndrome (SSs) with a prevalence ranging from 10 to 30 percent. <h3>Objectives</h3> The aim of this study was to evaluate the prevalence of SSs, characterize sSS patients and study the association between sSS and joint damage. <h3>Methods</h3> We conducted a cross-sectional study of RA patients, according to ACR/EULAR 2010 classification criteria, followed up at the Department of Rheumatology. Demographic characteristics and RA features of disease were collected. Pain was measured using a visual analogue scale (VAS). Disease activity was assessed by the Disease Activity Score (DAS 28). Functional disability was evaluated by the Health Assessment Questionnaire (HAQ). Joint destruction was assessed by the van der Heijde-modified Sharp Score. The diagnosis of SSs was made by a rheumatologist or confirmed by chart review. Data analysis was carried out using the SPSS 20 Software. p&lt;0.05 was considered statistically significant. <h3>Results</h3> One hundred and four patients with a mean±SD age of 49.37 ± 13.21 years were enrolled. Eighty-nine percent were females. Mean±SD duration of symptoms was 10.88 ± 9.17 years. Rheumatoid factor was present in 75% of patients with RA. Seventeen patients (16.3%) had SSs. RA subjects with sSS had longer RA disease duration and higher sharp scores. VAS pain and functional disability were significantly higher in patients with sSS (p&lt;0.05). The multivariate analysis showed that factors associated with joint destruction in patients with SSs were disease duration of RA (p=0.0001) and seropositivity by ACPA (P=0.006). <h3>Conclusions</h3> In our study, RA patients with sSS had worse joint damage, suggesting that sSS is a marker of a more aggressive disease. Therefore, it is important to screen sSS symptoms in patients with RA. <h3>Disclosure of Interest</h3> None declared
IgA and IgG Hypogammaglobulinemia Is a Constitutive Feature in Most Waldenstrom’s Macroglobulinemia Patients and May Be Related to Mutations Associated with Common Variable Immunodeficiency Disorder (CVID)
Authors: Steven Treon, Zachary Hunter, Bryan Ciccarelli, Yangsheng Zhou, Christina Hanzis, Robert Manning, Leukothea Ioakimidis, Lian Xu, Christopher Patterson, Massimo Morra
Journal: Blood (2008)
An Update on the Role of Thalidomide (THAL) in Total Therapy 2 (TT2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Analysis of Subgroups Defined by Standard Prognostic Factors (SPF) and Gene Expression Profiling (GEP)-Derived Subgroups.
Authors: John D. Shaughnessy, Jeffrey Haessler, Jerry Zeldis, Yongsheng Huang, Fenghuang Zhan, Jeffrey Sawyer, Elias Anaissie, Frits van Rhee, Guido Tricot, Joshua Epstein, Maurizio Zangari, Mauricio Pineda-Roman, Klaus Hollmig, John Crowley, Bart Barlogie
Journal: Blood (2006)
A Multicenter Randomized Phase II Trial of Mapatumumab, a TRAIL-R1 Agonist Monoclonal Antibody, In Combination with Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma (MM)
Authors: Andrew Belch, Atul Sharma, Andrew Spencer, Stefano Tarantolo, Nizar J Bahlis, Dinesh Doval, Gilles Gallant, Elizabeth Kumm, Jerry Klein, Asher A. Chanan-Khan
Journal: Blood (2010)
Rituximab-Bendamustine Cytarabine (R-BAC) As Frontline Therapy in Mantle Cell Lymphoma: A Single-Center Experience
Authors: Antonio Branca, Ilaria Gianesello, Luca Brugnaro, Tamara Berno, Silvia Imbergamo, Federica Lessi, Kety Sammartin, Fabrizio Vianello, Fausto Adami, Gianni Binotto, Carmela Gurrieri, Livio Trentin, Carlo Visco, Renato Zambello, Francesco Piazza, Gianpietro Semenzato
Journal: Blood (2015)
Surgical outcome analysis of 130 consecutive partial nephrectomies undertaken in the South Wales region and comparison with BAUS (STUKA) data
Authors: D. Teichmann, L. Whitehurst, R. Chaytor, I.l Omar, O. Naser, M. Kamarizan, A. Carter, S. Moosa, K. Narahari, R. Coulthard, N. Fenn
Journal: International Journal of Surgery (2016)
Adoptively Transferred CMV-Specific T-Cells Responsive to Immunodominant CMVpp65 Epitopes Extend Durable in-Vivo Suppression of Clonogenic CMVpp65 [+] Human Colon Carcinoma Cells in Comparison to T-Cells Responsive to Subdominant Epitopes
Authors: Aisha N Hasan, Annamalai Selvakumar, Tzu-Yun Kuo, Richard J O'Reilly
Journal: Blood (2015)
FCyIIIa Gene Polymorphisms as Response Predictor in Patients with Non-Hodgkin Lymphoma after Treatment with Anti-CD 20 Monoclonal Antibody (Rituximab).
Authors: Soledad Molnar, Mariana Nuñez, Maria L. Rizzi, Marcelo Lavarda, Maria I. Balseiro, Ricardo Ryser, Gustavo Jarchum
Journal: Blood (2007)
Hypermethylation of SH2-Containing Phosphatase-1 (SHP-1) and Suppressor of Cytokine Signaling-1 and -3 (SOCS-1 and -3) in Philadelphia Negative Chronic Myeloproliferative Disorders (Ph-CMPD).
Authors: Davide Rossi, Clara Deambrogi, Tiziana Lischetti, Michaela Cerri, Marianna Spunton, Silvia Rasi, Silvia Franceschetti, Annarita Conconi, Paola Riccomagno, Monia Lunghi, Daniela Capello, Gianluca Gaidano
Journal: Blood (2006)